Business Development
The Business Development team at Access Pharmaceuticals is interested in identifying out-licensing candidates, as well as alliance and merger opportunities for for our oncology products, as well as for our Cobalamin™ oral drug delivery and disease targeting technologies.
MuGard™ is our product for oral mucositis whtich has received US FDA marketing allowance. We are looking for commercial partners in North America and parts of the Far East.
ProLindac™ is our major chemotherapeutic compound, currently in Phase 2 clinical development.
Angiolix® and Prodrax® are anticancer products in preclinical development.
We are open to discussing arrangements of all types. To learn more about our products and capabilities please contact Phillip Wise by sending an email to the address below.